Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial

BACKGROUND: Anthracycline-induced cardiomyopathy (AIC) may be irreversible with a poor prognosis, disproportionately affecting women and young adults. Administration of allogeneic bone marrow–derived mesenchymal stromal cells (allo-MSCs) is a promising approach to heart failure (HF) treatment. OBJEC...

Descripción completa

Detalles Bibliográficos
Autores principales: Bolli, Roberto, Perin, Emerson C., Willerson, James T., Yang, Phillip C., Traverse, Jay H., Henry, Timothy D., Pepine, Carl J., Mitrani, Raul D., Hare, Joshua M., Murphy, Michael P., March, Keith L., Ikram, Sohail, Lee, David P., O’Brien, Connor, Durand, Jean-Bernard, Miller, Kathy, Lima, Joao A., Ostovaneh, Mohammad R., Ambale-Venkatesh, Bharath, Gee, Adrian P., Richman, Sara, Taylor, Doris A., Sayre, Shelly L., Bettencourt, Judy, Vojvodic, Rachel W., Cohen, Michelle L., Simpson, Lara M., Lai, Dejian, Aguilar, David, Loghin, Catalin, Moyé, Lem, Ebert, Ray F., Davis, Barry R., Simari, Robert D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781291/
https://www.ncbi.nlm.nih.gov/pubmed/33403362
http://dx.doi.org/10.1016/j.jaccao.2020.09.001

Ejemplares similares

Ejemplares similares